Clinical trial
An Intravenous, Open-label, Single-dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of rhLCAT in Subjects With Coronary Artery Disease
NCT01554800 is registered in ClinicalTrials.gov with MedImmune LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Intravenous, Open-label, Single-dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of rhLCAT in Subjects With Coronary Artery Disease
- Lead sponsor
- MedImmune LLC
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- March 31, 2012
- Completion date
- September 30, 2012
- Enrollment
- 16 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.